Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer

Williams, Andrew K.; Martínez, Carlos H.; Chen, Lu; Ng, Chee Kwan; Pautler, Stephen E.; Chin, Joseph L.

doi:10.1016/j.eururo.2010.12.012

Cited by 106 publications

(81 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have reported, based on our experience on 176 patients, a 10-year disease-free survival (DFS) of 39% for salvage CRYO. 7 For salvage HIFU, we reported 1-and 2-year progression-free survival rates of 62% and 48%, respectively. 9 For low-risk prostate cancer, Murat and colleagues reported the DFS rate of 53% for salvage HIFU at 40 months of follow-up.…”

Section: Discussionmentioning

confidence: 94%

“…The oncological outcomes of our series have previously been reported. [7][8][9] We tallied Clavien grade complications. For Groups 1, 2 and 3, we recorded the following Clavien I-II complications: 78, 49 and 13, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…[3][4][5] At our centre we have been treating radio-recurrent prostate cancer (RRPC) with both these energy-based modalities, transitioning from CRYO to HIFU. [6][7][8][9] We report our single centre and single surgeon (17 years) experience to highlight the learning curve and compare the morbidity of the two salvage treatment modalities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer

Siddiqui

Billia

Williams

et al. 2015

CUAJ

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer

Siddiqui

Billia

Williams

et al. 2015

CUAJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…Retrospective analysis shows that patients with low risk disease at initial diagnosis or pre-salvage PSA less than 5ng/mL had 3-year and 10-year bDFS rates of 73% and 64% respectively but those with high risk disease or pre-salvage PSA over 5ng/mL had rates of 11% and 6.7%. [23,24] Focal cryotherapy has been explored in the COLD database which reports 5-year bDFS of 46.5% with similar toxicity to whole gland CA. [25] Complication rates for CA include urinary retention (6.6-12%), incontinence (5.5-13%), recto-urethral fistula (1-3.3%) and erectile dysfunction (ED) in up to 80-90% of men.…”

Section: Salvage Radical Prostatectomy (Srp) Following Ebrtmentioning

confidence: 99%

Emerging Treatments for Recurrent Prostate Cancer

Hanna

Jones

2015

Future Oncol.

View full text Add to dashboard Cite

Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease. We consider salvage treatments aimed at those with local recurrence confined to the prostate gland, therapies for those presenting with metastatic recurrence and the approach to men presenting with a rising prostate-specific antigen but no demonstrable disease (M0). In general, men with recurrent disease are often under-represented in randomized clinical trials. Consequently, evidence to guide treatment for these men is often lacking and this needs to be addressed in order to improve and better define our approach to this problem in the future.

show abstract

“…Published data in terms of DFS have achieved ranges from 11 to 73% at 5 years [30,31]. Data from our institution have shown a DFS rate at 10 years of between 39 and 64% with presalvage PSA <5 ng/ml and presalvage Gleason score ≤7 being the best predictor of disease-free recurrence at 10 years [32]. Recently, Philippou et al [33] have reported a DFS rate at 2 years of 58% with a median PSA nadir of 0.20 ng/ml.…”

Section: Cryotherapymentioning

confidence: 99%

High-Intensity Focused Ultrasound and Cryotherapy as Salvage Treatment in Local Radio-Recurrent Prostate Cancer

2012

View full text Add to dashboard Cite

Background: Salvage high-intensity focused ultrasound (HIFU) and cryotherapy (CRYO) have emerged as interesting alternatives in the treatment of local radio-recurrent prostate cancer. Currently, recommendations concerning the use of CRYO and HIFU in the salvage setting are still evolving. Aim: The objective of this review was to analyze the results from studies on CRYO and HIFU as salvage treatment in local radio-recurrent prostate cancer. Materials and Methods: A National Center for Biotechnology Information PubMed search (www.pubmed.gov) was conducted from 1993 to 2011 using medical subject headings ‘High-Intensity Focused Ultrasound’, ‘Cryotherapy’, ‘Local Radio-Recurrent’ and ‘Prostate Cancer’. Results: In the past years, there have been several published series demonstrating promising acceptable morbidity and oncological outcomes in the short term for HIFU and in the intermediate term for CRYO. The introduction of newer-generation devices and technical modifications has facilitated reduction of complications associated with the procedures. As with any salvage treatment, careful patient selection and subsequent follow-up are principal points. Conclusions: HIFU and CRYO are promising salvage treatments in patients with local radio-recurrent prostate cancer. The risk of significant complications in the salvage setting is higher compared with primary therapy; therefore, the patients must be informed about the risk of complications and the modality of treatment. However, only further evaluation in formal prospective clinical trials will hopefully confirm their role in clinical practice.

show abstract

Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer

Cited by 106 publications

References 17 publications

Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer

Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer

Emerging Treatments for Recurrent Prostate Cancer

High-Intensity Focused Ultrasound and Cryotherapy as Salvage Treatment in Local Radio-Recurrent Prostate Cancer

Contact Info

Product

Resources

About